Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
about
Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.How to tackle congestion in acute heart failure.
P2860
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
@en
type
label
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
@en
prefLabel
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
@en
P2860
P1476
Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond.
@en
P2093
Frederik H Verbrugge
Pieter Martens
P2860
P2888
P356
10.1007/S11936-017-0522-X
P577
2017-03-01T00:00:00Z